Immunoglobulin Fc Fragments - Therapeutic use
Research News and Information

Friday, March 19, 2010

Branch-specific sialylation of IgG-Fc glycans by ST6Gal-I.

18 Oct 2009 Sialylated forms of the Fc fragment of immunoglobulin G, produced by the human alpha2-6 sialyltransferase ST6Gal-I, were identified as potent anti-inflammatory mediators in a mouse model of rheumatoid arthritis and are potentially the active ... Read more...

Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model.

21 May 2009 Humanization and modification of the Fc region of anti-human CD3 mAbs have greatly expanded their potential use in chronic T cell mediated diseases. However, low levels of cytokine release and immunogenicity may still impact a chronic dosing ... Read more...

Protection of immuno-compromised mice from lethal infection of Klebsiella pneumonia by rAAV2-BPI23-Fcgamma1 gene transfer.

29 Nov 2008 In previous research, chimerical BPI23-Fcgamma1 gene which consisted of human bactericidal/permeability increasing protein (BPI) gene of encoding the functional N terminus (amino acid residues 1 to 199) of human BPI and Fcgamma1 gene of encoding the ... Read more...

Latest indexed articles for 'Immunoglobulin Fc Fragments - Therapeutic use'

These are the very latest articles for this heading:

• Branch-specific sialylation of IgG-Fc glycans by ST6Gal-I. 18 Oct 2009
• Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model. 21 May 2009
• Protection of immuno-compromised mice from lethal infection of Klebsiella pneumonia by rAAV2-BPI23-Fcgamma1 gene transfer. 29 Nov 2008
• Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. 5 Oct 2008
• A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. 7 Aug 2008
• A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. 30 Jul 2008
• Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. 30 Jul 2008
• The antiinflammatory IgG. 15 Jul 2008
• When binding is enough: nonactivating antibody formats. 7 Jul 2008
• Considerations for the development of therapeutic monoclonal antibodies. 30 Jun 2008
• CD24 cross-linking induces apoptosis in, and inhibits migration of, MCF-7 breast cancer cells. 22 Apr 2008
• Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. 16 Apr 2008
• Immunoglobulin-like transcript 3-Fc suppresses T-cell responses to allogeneic human islet transplants in hu-NOD/SCID mice. 14 Apr 2008
• Engineering therapeutic monoclonal antibodies. 30 Mar 2008
• Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer. 13 Jan 2008
• Dectin-1 Fc targeting of aspergillus fumigatus beta-glucans augments innate defense against invasive pulmonary aspergillosis. 15 Dec 2007
• A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma. 30 Sep 2007
• Improving therapeutic properties of protein drugs through alteration of intracellular trafficking pathways. 20 Sep 2007
• Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. 29 Aug 2007
• Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. 13 Aug 2007

See a longer list of these articles.

Technical information about 'Immunoglobulin Fc Fragments'

Definition: Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.

Registry Number: 0

Descriptor UI: D007141

Alternative terms: Immunoglobulin Fc Fragments; Fc Fragments, Immunoglobulin; Immunoglobulins, Fc Fragment; Fc Fragment Immunoglobulins; Fragment Immunoglobulins, Fc; Immunoglobulin Fc Fragment; Fc Fragment, Immunoglobulin; Immunoglobulins, Fc; Fc Fragments; Fc Immunoglobulins;

Related Mesh Headings: Receptors, Fc;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; biosynthesis; blood; cerebrospinal fluid; classification; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacology; physiology; poisoning; radiation effects; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications;

Pharmacological Action: Immunologic Factors;

Tree Number: D12.776.124.486.485.538.500; D12.776.124.486.485.680.697; D12.776.124.790.651.538.500; D12.776.124.790.651.680.660; D12.776.377.715.548.538.500; D12.776.377.715.548.680.660;

History Note: 2006 (1973)

Technical Notes: DF: IG FC